The estrogen receptor-a (ER) plays a crucial role in normal breast development and is also linked to development and progression of mammary carcinoma. The transcriptional repression of ER-a gene in breast cancer is an area of active investigation with potential clinical significance. However, the molecular mechanisms that regulate the ER-a gene expression are not fully understood. Here we show a new molecular mechanism of ER-a gene inactivation mediated by pRb2/p130 in ER-negative breast cancer cells. We investigated in vivo occupancy of ER-a promoter by pRb2/p130-E2F4/5-HDAC1-SUV39 H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 complexes, and provided a link between pRb2/ p130 and chromatin-modifying enzymes in the regulation of ER-a transcription in a physiological setting. These findings suggest that pRb2/p130-multimolecular complexes can be key elements in the regulation of ER-a gene expression and may be viewed as promising targets for the development of novel therapeutic strategies in the treatment of breast cancer, especially for those tumors that are ER negative.
Introduction
Many studies have identified oncogenes and tumor suppressor genes as markers of cellular transformation in several tissue types, such as colon, pancreas and lung, whereas comparable studies in breast cancer have met with limited success (West et al., 2001) . This reflects the difficulty in finding genetic and epigenetic alterations in a significant proportion of breast cancers and the phenotypic heterogeneity of breast cancer itself. The identification of the molecular targets for an early diagnosis of breast cancer could open the door to improved diagnosis and treatment based on a molecular diagnosis. Most mammary carcinomas contain estrogen receptors (ERs), which are important factors for diagnosis and prognosis and for therapeutic choices (Osborne, 1998) . Estrogens are direct mitogens for hormone-responsive human breast cancer cells, where they promote cell cycle progression and induce the transcriptional activation of 'immediate-early' and cyclin genes. The ER-a and its ligand (17b-estradiol) play a crucial role in normal breast development and have also been linked to mammary carcinogenesis and clinical outcome in breast cancer patients. However, up to one-third of breast cancers lack ER-a at the time of diagnosis, and a fraction of breast cancers that are initially ER-a positive lose ER during tumor progression (Hortobagyi, 1998) . In a significant fraction of breast cancers the absence of ER-a gene expression has been associated with the aberrant methylation of its CpG islands (Weigel and Coninck, 1993; Hortobagyi, 1998) . Recent data indicate that chromatin inactivation mediated by histone deacetylation and DNA methylation is a critical component of ER-a silencing in human breast cancer cells. In vitro studies have shown that DNA (cytosine-5) methyltransferase (DNMT1) interacts physically with either histone deacetylase 1 (HDAC1) or histone deacetylase 2 (HDAC2) and that cotreatment with DNMT1 and HDAC inhibitors can synergistically induce ER-a gene expression in ER-anegative breast cancer cells (Robertson et al., 2000; Rountree et al., 2000; Yang et al., 2001) . Therefore, HDACs and DNMTs may be potential targets for therapeutic intervention in the treatment of a subset of ER-a-negative breast cancers (Davis et al., 2000; Yang et al., 2000 Yang et al., , 2001 . Transcription in eukaryotic cells is strongly influenced by the manner in which DNA is packaged. There is abundant evidence that the structure and chemical composition of chromatin directly affects gene expression. Histones are the primary structural components of chromatin. The nucleosome is the basic repeating unit of chromatin and further compaction of this structure, with the aid of the histone H1 and other nonhistone proteins, leads to condensed chromatin state (Hayes and Hansen, 2001) . In this way the chromatin is inaccessible to the transcriptional machinery, resulting in gene silencing. Recent studies have revealed that there are different types of protein complexes capable of altering chromatin, and these may act in a physiological context to modulate DNA accessibility (Vignali et al., 2000) . Chromatin structure and function are controlled, at least in part, through post-translational modifications of nucleosomal histones. The core histone tails are susceptible to a variety of covalent modifications, including acetylation, methylation, phosphorylation and ubiquitination. Different studies collectively support the histone code hypothesis (Strahl and Allis, 2000) . This hypothesis suggests that the presence of a given modification on histone tails may dictate or prevent the presence of a second modification elsewhere on the same histone. In this way, these modifications serve as marks for the recruitment of different proteins or protein complexes, which regulate chromatin functions, such as gene expression. Many studies have now shown that DNA methylation is also important for transcriptional silencing. Therefore, it has been proposed that DNA methylation and histone deacetylation might work together to establish a repressive chromatin environment and silence gene expression (Cameron et al., 1999) . The formation of transcriptional repression complexes such as DNMT1/HDAC is emerging as an important mechanism in gene expression regulation (Laird and Jaenisch, 1996; Grunstein, 1997; Lin et al., 1998; Struhl, 1998) . Aberrant recruitment of HDAC activity has been associated with the development of certain human cancers (Nan et al., 1998) and changes in the patterns of CpG methylation appear to be an intrinsic feature of human malignancy (Jones et al., 1998) . However, the mechanisms of gene silencing by methylation remain poorly understood. Recent studies suggest that histone methylation, similar to histone deacetylation, might function in concert with DNA methylation (Bird and Wolffe, 1999) . Many studies have now shown that histone methylation on lysines, by the histone methyl transferase SUV39H1, is important for transcriptional silencing. Recent observations suggest that a specific chromatin structure involving methylated histones may be necessary for DNA methylation to occur (Ng and Bird, 1999) .
Several mechanisms have been proposed to account for transcriptional repression by the Rb proteins (Dunaief et al., 1994; Trouche et al., 1997; MagnaghiJaulin et al., 1998) . Some of the proposed models stress the importance of chromatin structure in regulating transcriptional activity. Active repression by Rb family members could involve a mechanism by which condensed chromatin structure is enhanced through histone deacetylation and methylation. Rb proteins have been shown to repress E2F-dependent transcription by recruiting HDAC1/2 (Iavarone and Massague, 1999; Stiegler et al., 1998) . Recent data have shown that pRb2/p130 and p107 are able to interact physically with HDAC1 through the A/B pocket domains (Ferreira et al., 1998; Magnaghi-Jaulin et al., 1998; Iavarone and Massague, 1999) . Repression of E2F-responsive promoters in quiescent cells is associated with E2F-4 and pRb2/p130 recruitment and low histone acetylation levels. Recently, different studies have shown that SUV39H1 is involved in transcriptional repression by the retinoblastoma protein Rb1/p105 (Vandel et al., 2001) . These data suggest an interesting link between Rb family members and chromatin-modifying enzymes in the repression of promoters at euchromatic sites.
Here we show that there are two multimolecular complexes, pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-DNMT1-SUV-39H1, bound to the ER-a promoter but not to the ER-b promoter, in breast cancer cells. We suggest that different physiologically important enzymes could be recruited by pRb2/p130 on the ER-a promoter. The identity and temporal specificity of recruited enzymatic activities in complexes by pRb2/p130 might control chromatin organization by inducing different acetylation and methylation levels, and could be important for the silencing or transcriptional regulation of the ER-a gene.
Results

The density of methylated sites of the ER-a and ER-b promoters can influence the expression of these genes
We investigated the DNA methylation levels of ER-a promoter in cycling MDA-MB-231 (estrogen-negative), MCF-7 (estrogen-positive), and MCF-12A (normal epithelial mammary) cell lines. We analysed five regions of ER-a promoter by methylation-specific-PCR (MSP) and we found a different density of CpG dinucleotides methylated in the MDA-MB-231 and MCF-7 breast cancer cell lines. In the MDA-MB-231 cells, we found that the regions A, B, C, E on the ER-a promoter are methylated and the region D is unmethylated ( Figure 1a ). On the contrary, in MCF-7 cell line, we Figure 1b) . In MCF-12A, we found that all the analysed regions of ER-a promoter are unmethylated (data not shown). Moreover, we analysed the region D of ER-a promoter in primary breast tumors and found this region methylated in five samples (Figure 1c) . Interestingly, these primary tumors were classified as ER-a positive at the time of diagnosis via immunohistochemistry (data not shown). A large number of cases will have to be systematically studied to gain a clear picture of DNA methylation significance as a prognostic factor in human breast cancer. Moreover, we investigated the methylation level of two ER-b promoter regions and we found both methylated in MCF-7 and MDA-MB-231 (Figure 1d ). Density of CpG dinucleotide, distance of methylation sites from the promoter region, and size of the modified fragments have been proposed to be critical factors influencing gene silencing. A short region of methylated DNA can influence the expression of flanking unmodified promoter. Our data suggest that high density of CpG sites methylated on ER-a promoter could be responsible of gene silencing in ER-negative MDA-MB-231 cells. Moreover, the presence of ER-b methylation in both MDA-MB-231 and MCF-7 cell lines could explain the lack of ER-b expression in these cell lines. Actually, it is not fully understood whether those breast cancers that lack ER expression at diagnosis arise from an ER-negative compartment within the mammary epithelium or represent evolution from an ER-positive to ER-negative state (Parl, 2000) . The heterogeneity of ER gene methylation may explain why some originally ER-positive primary tumors recur as ER-negative tumors. During tumor progression, a selective pressure could lead to an accumulation of cells with methylated and transcriptionally repressed ER genes. However, these observations prompt us to explore the molecular mechanisms controlling the methylation and transcriptional repression of ERs in breast cancer.
In vivo ER promoters occupancy by pRb2/p130
We used a modified procedure of formaldehyde crosslinked chromatin immunoprecipitation assay (XChIP) in combination with Western blotting and PCR to study in vivo ER-a and ER-b promoter occupancy by pRb2/ p130. We found that complexes formed by pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 bound the ER-a promoter but not the ER-b promoter, in cycling MCF-7 and MDA-MB-231 breast cancer cell lines, respectively (Figure 2a, b, c and d) . Interestingly, the ER-a promoter region, bound by the aforementioned complexes, contains two E2F sites near the transcription start that could be potential sites of binding for the pRb2/130 multimolecular complexes. In addition, TATA and CAAT boxes are located downstream of the E2F sites. These observations suggest that this ER-a promoter region is important to control the transcription of this gene, and strengthen the idea that the presence of pRb2/ p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 complexes could regulate ER-a transcription, perhaps by modulating chromatin packaging and the accessibility to the basal transcription machinery. It is possible to speculate that pRb2/p130 could mediate transcriptional repression by first bringing onto the ER-a promoter a specific histone methyltransferase (SUV39H1) and deacetylase (HDAC1) for transient gene silencing. In a second repression step, pRb2/p130 could further recruit the DNMT1 to methylate DNA for long-term gene silencing. This hypothesis could explain our results. In fact, we found that in the ER-a-positive MCF-7 cell line there is only one methylated CpG region among those we screened and that the complex found by XChIP seems to be depleted of DNMT1. On the other hand, the ER-anegative MDA-MB-231 cell line showed methylation in the majority of the CpG regions screened and the complex contained DNMT1. The shift from ER-a activation to ER-a silencing could depend on balance among histone deacetylation/acetylation, histone methylation, and DNA methylation possibly regulated by replacement of histone acetyl transferase p300 with DNMT1 in pRb2/p130-E2F4/5-HDAC1-SUV39H1 complexes.
Collectively, these results provide the physiological evidence for a link between pRb2/p130 and chromatinmodifying enzymes in ER-a, but not ER-b, transcriptional regulation in breast cancer cell lines.
Histone acetylation levels of ER-a promoter correlates with transcriptional activation
Having identified the pRb2/p130 multimolecular complexs on the ER-a promoter, we then determined the relative levels of ER-a histone H3 and H4 acetylation in MDA-MB-231 and MCF-7 cell lines. We found a good correlation between acetylation of histone H3 and H4, and the activation of ER-a gene. Interestingly, we detected levels of acetylated histone H4 and H3 in MCF-7 cells, whereas only the histone H4 acetylation was detected in MDA-MB-231cell line (Figure 3) . The interplay among pRb2/p130, HDAC1, p300, SUV39H1, and DNMT1 is not clear at this point, but the presence of different enzymes in complex with pRb2/p130 suggests that these complexes could mediate HAT activity with distinct effects. In other words, the presence of DNMT1 in complex with pRb2/p130, HDAC1, and SUV39H1 might function in the maintenance of the ER-a transcriptional repressive state by occluding p300 association in MDA-MB-231 cells and leading to higher-order chromatin structure that denies assess to transcription factors. On the other hand, the absence of DNMT1 in pRb2/p130 multimolecular complex could facilitate the p300 recruitment required to maintain high levels of histone acetylation on ER-a promoter thus leading to its transcriptional activation in MCF-7 cells. Furthermore, the absence of histone H3 acetylation in MDA-MB-231 is not surprising as correlates with gene silencing. In fact, it has been reported that methylation and acetylation of histone H3 are mutually exclusive and that H3 acetylation pRb2/p130-E2Fs complexes and the transcription of ER-a M Macaluso et al correlates with transcriptional activation. Consequently, our hypothesis is that in MDA-MB-231, the SUV39H1 can methylate histone H3 while in MCF-7 its histone methyltransferase activity is prevented by p300 activity, which can acetylate histone H3.
Discussion
There is mounting evidence that the ER-a plays a crucial role in normal breast development and is also linked to development and progression of mammary carcinoma (Hortobagyi, 1998; Osborne, 1998; Yang, 2001) . The transcriptional repression of ER-a gene in breast cancer is an area of active investigation with potential clinical significance. However, the molecular mechanisms that regulate the ER-a gene expression are not fully understood. Recently, it has been suggested that different classes of chromatin-modifying factors may be recruited to promoters as multienzyme corepressor complexes, and various chromatin-modifying activities could be specifically targeted to promoters in a variety of transcriptional contexts (Davis et al., 2000; Strahl and Allis, 2000; Sif et al., 2001; La Sala et al., 2003 Figure 2 In vivo ER-a promoter occupancy by pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1-p300 in cycling MCF-7 and MDA-MB-231 breast cancer cell lines.Formaldehyde crosslinked chromatin immunoprecipitation (XChIP) analysis was performed as described in Materials and methods, using pRb2/p130 as immunoprecipitating antibody. The washed immunocomplexes-DNA/ protein A were divided for Western blotting and DNA extraction: (a) western blot of chromatin immunoprecipitated after crosslinking was performed using antibodies against pRb2/p130, E2F4, E2F5, HDAC1, SUV39H1, p300, and DNMT1. The same blot was stripped and reprobed sequentially. The mock lane corresponds to a negative control immunoprecipitation using an irrelevant antibody. (b) The DNA was extracted from the immunoprecipitates, and amplified by PCR using specific primers spanning ER-a and ER-b promoter fragments. Input represents the cross-linked chromatin before the immunoprecipitation. (c) Direct sequencing chromatogram of one of PCR product shown in b. (d) XChIP analyses were also performed using E2F4, E2F5, HDAC1, SUV39H1, p300, and DNMT1 as immunoprecipitating antibodies PCR results using the same primers spanning ER-a as those described in b are shown here acH3 acH4
MDA-MB231
MCF-7 MCF-7 MDA-MB-231 ER-α Input Input Figure 3 Histone acetylation levels of ER-a promoter in MDA-MB231 and MCF7 breast cancer cell lines. Formaldehyde crosslinked chromatin immunoprecipitation (XChIP) was performed using antibodies against acetylated histones H3 and H4. The DNA was extracted from immunoprecipitated and amplified using specific primers for the ER-a promoter. The input represents the total chromatin prior to immunoprecipitation pRb2/p130-E2Fs complexes and the transcription of ER-a M Macaluso et al ER-a gene inactivation mediated by pRb2/p130 in ERnegative breast cancer cells. We show in vivo occupancy of ER-a promoter by pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-DNMT1-SUV39H1 complexes, and provide a link between pRb2/p130 and chromatin-modifying enzymes in the regulation of ER-a transcription in a physiological setting. Therefore, our hypothesis is that a different set of enzymatic activities could be recruited in multimolecular complexes by pRb2/p130 on the ER-a promoter. The identity and temporal specificity of recruited enzymes could control chromatin organization by inducing different histone acetylation and methylation levels and the accessibility to the basal transcription machinery. Our results suggest that the recruitment of SUV39H1, HDAC1, and p300 by pRb2/p130 could regulate the expression level of ER-a in MCF-7, and that further recruitment of DNMT1 (with the concomitant release of p300/CBP) could be required for long-term ER-a gene silencing in MDA-MB-231 cells (Figure 4a and b) . This observation could provide further information as to how the DNA methylation mechanism occurs in ER-negative cells.
Collectively, these data suggest that multimolecular complexes recruited by pRb2/p130 can be key elements in the regulation of ER-a gene expression and may be viewed as promising targets for the development of novel therapeutic strategies in the treatment of breast cancer, especially for those tumors that are ER negative.
Materials and methods
Cell lines and primary tumors
The breast carcinoma cell lines, MCF-7 (ER-positive), MDA-MB-231 (ER-negative), and the mammary epithelial cell line MCF-12A were obtained from ATCC (Rockville, MD, USA) and were cultured according to the manufacturer's protocols. The breast primary tumors were selected on the basis of ER status.
MSP
Genomic DNA from cell lines and primary tumors were subjected to modification by sodium bisulfite in order to convert unmethylated cytosines but not methylated cytosines to uracils (GpGenome DNA modification kit, Intergene . DNA modified by bisulfite reaction was used to amplify regions within ER-a and ER-b promoters containing CpG islands by PCR. In all, 10 pairs of ER-a primers (Lapidus et al, 1998) and four pairs of ER-b primers (region a: bM1 forward 5 0 -AAATTTGTTAGTTGGATTAGATCGA-3 0 ; bM2 reverse 5 0 -TTCAAAAAAACCTTTAATTAAAACG-3 0 ; bU1 forward 5 0 -AAATTTGTTAGTTGGATTAGATTGA-3 0 ; bU2 reverse 5 0 -CAAAAAAACCTTTAATTAAAACACA-3 0 ; region b: bM3 reverse 5 0 -AAACGACGAACGCTAAACC-GAAAAAAAA-3 0 ; bU3 reverse 5 0 -AACAAACAACAAAC-ACTAAACCAAAAAAAAA-3 0 ) were designed to discriminate between modified (M) and unmodified (U) DNA. As control, wild-type primers were used to amplify the DNA not subjected to sodium bisulfite modification (WTa1 forward 5 0 -AGGAGCTGGCGGAGGGCGTTCG-3 0 ; WTa2 reverse 5 0 -AGCGCATGTCCCGCCGACACGC-3 0 ; WTb1 forward 5 0 -CGAGCGCTGGGCCGGGGAGGG-3 0 ; WTb2 reverse 5 0 -CTCCCGGCGCGCGCCCCGCC-3 0 ).
In vivo ER-a and ER-b promoter occupancy by pRb2/p130, E2F4/5, HDAC1, p300 SUV39H1, DNMT1 using formaldehyde crosslinked chromatin immunoprecipitation assay (XChIP), in cycling breast cell lines
We performed chromatin immunoprecipitations using a modified procedure of previously published methods (Orlando et al. 1997; Keller et al., 2002) , in combination with Western blot and PCR. Approximately 1 Â 10 6 MCF-7 and MDA-MB-231 cells were crosslinked by adding formaldehyde (1% final concentration) directly to culture medium, and incubated for 8 min at 371C.
After removal of the medium, cells were washed three times on plates with cold phosphate-buffered saline (PBS) containing protease inhibitors (1 mm phenylmethylsulfonyl fluoride, 1 mg/ ml aprotinin and 1 mg/ml pepstatin A), scraped, and washed again twice in cold PBS. The cell pellet was resuspended in SDS lysis buffer (1% SDS, 10 mm EDTA, 50 mm Tris-HCl, pH 8.1), incubated for 10 min on ice, sonicated to shear DNA to lengths between 300 and 500 bp, and centrifuged for 10 min at 13 000 rpm at 41C. Sonicated cell supernatant was diluted in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mm EDTA, 16.7 mm Tris-HCl, pH 8.1, 167 mm NaCl), and precleared with Salmon Sperm DNA/protein A agarose at 41C for 2 h, this was done twice. The agarose was pelleted and the supernatant fraction collected and incubated overnight at 41C with the immunoprecipitating antibody. Each immunoprecipitation was performed using 3-4 mg of antibodies against pRb2/p130, E2F4, E2F5, HDAC1, SUV39H1, p300, DNMT1 acetylated histones H3 or H4 (Santa Cruz Biotechnology, CA and Upstate Biotechnology, MA, USA). As negative controls, we performed a no-antibody immunoprecipitations by incubating the supernatant fraction with Salmon Sperm DNA/ protein A agarose, and immunoprecipitations with an irrelevant antibody. The immunocomplexes-DNA were recovered with 50 ml of Salmon sperm DNA/protein A agarose, and washed two times with low-salt wash buffer (1% Triton X-100, 0.1% SDS, 2 mm EDTA, 20 mm Tris-HCl, pH 8.1, 150 mm NaCl), with high-salt wash buffer (1% Triton X-100, 0.1% SDS, 2 mm EDTA, 20 mm Tris-HCl, pH 8.1, 500 mm NaCl), with lithium wash buffer (0.25 M LiCl, 1% NP40, 1% deoxycholate, 1 mm EDTA, 10 mm Tris-HCl, pH 8.1), and four times with 1 Â TE buffer (10 mm Tris-HCl, 1 mm EDTA, pH 8.0). The washed immunocomplexes-DNA/protein A were divided for Western blotting and DNA extraction. For Western blot analysis, the samples were eluted from the beads, loaded in SDS-polyacrylamide gel, and transferred to a membrane. The immunoblotting was performed using antibodies against pRb2/p130, E2F4, E2F5, HDAC1, SUV39H1 DNMT1 and p300 (Santa Cruz Biotechnology, CA, USA).
For DNA extraction, elution buffer (1% SDS, 0.1 M NaHCO 3 ) was added to the washed immunocomplexes-DNA/protein A. Crosslinks were reversed by incubating samples at 651C overnight, and DNA extracted with phenol : -chloroform and ethanol precipitation. Pellets were resuspended in TE, and PCR was performed using specific primers to amplify the ER-a (forward 5 0 -AGGAGCTGGCG-GAGGGCGTTCG-3 0 ; reverse 5 0 -AGCGCATGTCCCGCC-GACACGC-3 0 ) and ER-b (forward 5 0 -CGAGCGCTGGG-CCGGGGAGGG-3 0 ; reverse 5 0 -CTCCCGGCGCGCGCCC-CGCC-3 0 ) promoters.The total chromatin (input) was used as a positive control in PCR reactions.
